Camptosar Label Revision Strengthens Monitoring Of Patients With Diarrhea
Pharmacia Camptosar revised labeling strengthens recommendations on monitoring patients with diarrhea
You may also be interested in...
Pharmacia will submit a labeling change proposal for its colorectal cancer therapy Camptosar by the end of the year based on FDA's Oncologic Drugs Advisory Committee Dec. 6 review of postmarketing safety
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials